Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Activated in North America and Europe Data at AACR and SGO Annual Meetings Highlight Patient Selection Strategy for FORWARD I and Breadth of ADC Expertise Mirvetuximab Soravtansine Safety and Efficacy Data to be Presented at ASCO Annual Meeting
Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2
Positive Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer; Detailed Results to be Presented in Plenary Session at SGO in March Mirvetuximab BLA On Track for Submission this Quarter IMGN632 Triplet Data Demonstrating Manageable Safety Profile and Encouraging
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Funds Operations into the Second
Accelerated Approval Pathway Defined for Mirvetuximab Soravtansine in Ovarian Cancer; Pivotal SORAYA Trial Expected to Enroll First Patient in Q1 2020 Phase 3 Confirmatory MIRASOL Trial for Mirvetuximab Enrolling Patients Updated IMGN632 AML and BPDCN Monotherapy Data Presented at ASH $97.6 Million
Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019 Encouraging Clinical Data from Novel IGN Pipeline Highlighted in Two Oral Presentations at ASH 2018 Sale of Kadcyla ® Royalty Tail for $65 Million Further Strengthens Financial Position Conference
Significant Operational and Financial Progress in 2017 with a Robust Set of Data and Events Expected in 2018 Mirvetuximab Soravtansine Phase 3 FORWARD I Trial to Complete Enrollment by Mid-Year; FORWARD II Combination Data to be Presented Throughout 2018 Novel ADC Pipeline Continues to Advance with
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 12, 2020-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM")
Review of Data from First 10 Patients Demonstrates Significant Activity and Favorable Tolerability in Both De Novo BPDCN Patients and Those with a P rior or Concomitant Hematologic Malignancy (PCHM) Following Discussion with FDA, CADENZA Patients to be Segmented into De Novo and PCHM BPDCN
Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration ( FDA )